SK284623B6 - Použitie farmaceutickej kombinácie na liečenie závislosti od alkoholu - Google Patents

Použitie farmaceutickej kombinácie na liečenie závislosti od alkoholu Download PDF

Info

Publication number: SK284623B6
Authority: SK; Slovakia
Prior art keywords: treatment; nmda receptor; modulator; opioid antagonist; alcohol
Prior art date: 1998-03-26

Application number

SK1428-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK14282000A3 (sk

Inventor

Martine Daoust

Yves Bonhomme

Philippe Durbin

Original Assignee

Lipha

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-26

Filing date

1999-03-26

Publication date

2005-08-04

1999-03-26 Application filed by Lipha filed Critical Lipha

2001-05-10 Publication of SK14282000A3 publication Critical patent/SK14282000A3/sk

2005-08-04 Publication of SK284623B6 publication Critical patent/SK284623B6/sk

Links

208000007848 Alcoholism Diseases 0.000 title claims abstract description 13
201000007930 alcohol dependence Diseases 0.000 title claims abstract description 13
239000011885 synergistic combination Substances 0.000 title claims abstract description 6
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims abstract description 24
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims abstract description 23
AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims abstract description 15
229960004047 acamprosate Drugs 0.000 claims abstract description 14
239000003401 opiate antagonist Substances 0.000 claims abstract description 14
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims abstract description 14
229940063673 spermidine Drugs 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
238000002360 preparation method Methods 0.000 claims description 4
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 3
229960004127 naloxone Drugs 0.000 claims description 3
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
230000002195 synergetic effect Effects 0.000 claims 1
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract description 19
229960003086 naltrexone Drugs 0.000 abstract description 19
238000004519 manufacturing process Methods 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
241000700159 Rattus Species 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000002775 capsule Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000037396 body weight Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
229920000768 polyamine Polymers 0.000 description 6
239000004471 Glycine Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000003887 narcotic antagonist Substances 0.000 description 4
108091006146 Channels Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000556 agonist Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229940075993 receptor modulator Drugs 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229960005168 croscarmellose Drugs 0.000 description 2
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000001722 neurochemical effect Effects 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000002747 voluntary effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
229940122459 Glutamate antagonist Drugs 0.000 description 1
229940127337 Glycine Antagonists Drugs 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
229950004794 dizocilpine Drugs 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000009540 excitatory neurotransmission Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000003825 glutamate receptor antagonist Substances 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 1
AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 1
229960003998 ifenprodil Drugs 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
QXUAFCKBYYPTPQ-ZWKAXHIPSA-L magnesium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol octadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QXUAFCKBYYPTPQ-ZWKAXHIPSA-L 0.000 description 1
238000013289 male long evans rat Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000008385 outer phase Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1428-2000A 1998-03-26 1999-03-26 Použitie farmaceutickej kombinácie na liečenie závislosti od alkoholu SK284623B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98400723A EP0945133A1 (en)	1998-03-26	1998-03-26	Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
PCT/EP1999/002337 WO1999048500A1 (en)	1998-03-26	1999-03-26	Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (2)

Publication Number	Publication Date
SK14282000A3 SK14282000A3 (sk)	2001-05-10
SK284623B6 true SK284623B6 (sk)	2005-08-04

Family

ID=8235311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1428-2000A SK284623B6 (sk)	1998-03-26	1999-03-26	Použitie farmaceutickej kombinácie na liečenie závislosti od alkoholu

Country Status (17)

Country	Link
US (1)	US6512009B1 (cs)
EP (2)	EP0945133A1 (cs)
KR (1)	KR20010034678A (cs)
AT (1)	ATE230993T1 (cs)
AU (1)	AU758569B2 (cs)
BR (1)	BR9909138A (cs)
CA (1)	CA2325739C (cs)
CZ (1)	CZ296367B6 (cs)
DE (1)	DE69904922T2 (cs)
DK (1)	DK1063995T3 (cs)
ES (1)	ES2190205T3 (cs)
HU (1)	HU226555B1 (cs)
NO (1)	NO319313B1 (cs)
PL (1)	PL193241B1 (cs)
RU (1)	RU2226107C2 (cs)
SK (1)	SK284623B6 (cs)
WO (1)	WO1999048500A1 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6913761B1 (en) *	1998-07-20	2005-07-05	Peptech Limited	Bioimplant formulation
US8052982B2 (en)	1998-07-20	2011-11-08	Peptech Animal Health Pty Limited	Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) *	2000-01-22	2001-07-26	Albert Shulman	Methods for the treatment of substance abuse
EP1262196A3 (en) *	2001-05-23	2002-12-18	Pfizer Products Inc.	Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) *	2001-06-18	2003-01-02	Hf Arzneimittelforsch Gmbh	Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) *	2001-09-24	2004-09-16	Garbil Pharma Investigacion Chile Ltda	Aminas como agentes anti-alcoholismo.
PT2561860T (pt)	2002-05-31	2018-05-08	Titan Pharmaceuticals Inc	Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
ATE482695T1 (de)	2002-12-13	2010-10-15	Durect Corp	Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US20040224020A1 (en) *	2002-12-18	2004-11-11	Schoenhard Grant L.	Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CA2520613C (en)	2003-03-31	2012-12-04	Titan Pharmaceuticals, Inc.	Implantable polymeric device for sustained release of dopamine agonist
WO2004110400A2 (en) *	2003-05-30	2004-12-23	Titan Pharmaceuticals, Inc.	Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) *	2005-11-03	2007-05-03	Alkermes, Inc.	Methods and compositions for the treatment of brain reward system disorders by combination therapy
JP2010513569A (ja) *	2006-12-19	2010-04-30	ユニバーシティオブバージニアパテントファウンデーション	アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
WO2009075782A1 (en) *	2007-12-06	2009-06-18	Durect Corporation	Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
ES2430940T3 (es)	2008-02-28	2013-11-22	University Of Virginia Patent Foundation	Gen del transportador de serotonina y tratamiento del alcoholismo
US20100260844A1 (en)	2008-11-03	2010-10-14	Scicinski Jan J	Oral pharmaceutical dosage forms
HUE035574T2 (en)	2010-07-02	2018-05-28	Univ Virginia Patent Foundation	Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US20130096173A1 (en)	2011-09-09	2013-04-18	Bankole A. Johnson	Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) *	2012-02-29	2013-02-27	Станислав Анатольевич Кедик	Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CA2905131A1 (en)	2013-03-15	2014-09-18	Durect Corporation	Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) *	2013-05-10	2013-06-19	Dalgleish Angus	Therapeutic
US12274794B2 (en)	2016-07-06	2025-04-15	Orient Pharma Co., Ltd.	Oral dosage form with drug composition, barrier layer and drug layer
US20240350433A1 (en) *	2021-08-17	2024-10-24	Yale University	Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4882335A (en) *	1988-06-13	1989-11-21	Alko Limited	Method for treating alcohol-drinking response
JPH11505547A (ja) *	1996-03-13	1999-05-21	エールユニバーシティ	ナルトレキソン及び関連化合物を用いる禁煙処置

1998
- 1998-03-26 EP EP98400723A patent/EP0945133A1/en not_active Withdrawn
1999
- 1999-03-26 CA CA002325739A patent/CA2325739C/en not_active Expired - Fee Related
- 1999-03-26 ES ES99916907T patent/ES2190205T3/es not_active Expired - Lifetime
- 1999-03-26 WO PCT/EP1999/002337 patent/WO1999048500A1/en not_active Ceased
- 1999-03-26 HU HU0101546A patent/HU226555B1/hu not_active IP Right Cessation
- 1999-03-26 CZ CZ20003525A patent/CZ296367B6/cs not_active IP Right Cessation
- 1999-03-26 BR BR9909138-0A patent/BR9909138A/pt not_active IP Right Cessation
- 1999-03-26 SK SK1428-2000A patent/SK284623B6/sk not_active IP Right Cessation
- 1999-03-26 DK DK99916907T patent/DK1063995T3/da active
- 1999-03-26 PL PL343069A patent/PL193241B1/pl not_active IP Right Cessation
- 1999-03-26 AU AU35226/99A patent/AU758569B2/en not_active Ceased
- 1999-03-26 DE DE69904922T patent/DE69904922T2/de not_active Expired - Lifetime
- 1999-03-26 AT AT99916907T patent/ATE230993T1/de active
- 1999-03-26 RU RU2000126790/15A patent/RU2226107C2/ru not_active IP Right Cessation
- 1999-03-26 US US09/647,091 patent/US6512009B1/en not_active Expired - Lifetime
- 1999-03-26 KR KR1020007010649A patent/KR20010034678A/ko not_active Ceased
- 1999-03-26 EP EP99916907A patent/EP1063995B1/en not_active Expired - Lifetime
2000
- 2000-09-25 NO NO20004788A patent/NO319313B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1063995A1 (en)	2001-01-03
DE69904922T2 (de)	2004-01-08
NO319313B1 (no)	2005-07-11
KR20010034678A (ko)	2001-04-25
ATE230993T1 (de)	2003-02-15
WO1999048500A1 (en)	1999-09-30
HUP0101546A3 (en)	2002-10-28
CA2325739C (en)	2007-05-15
AU758569B2 (en)	2003-03-27
EP0945133A1 (en)	1999-09-29
PL343069A1 (en)	2001-07-30
RU2226107C2 (ru)	2004-03-27
PL193241B1 (pl)	2007-01-31
SK14282000A3 (sk)	2001-05-10
CA2325739A1 (en)	1999-09-30
BR9909138A (pt)	2000-12-05
AU3522699A (en)	1999-10-18
US6512009B1 (en)	2003-01-28
NO20004788D0 (no)	2000-09-25
HK1032542A1 (en)	2001-07-27
DK1063995T3 (da)	2003-03-10
HUP0101546A2 (hu)	2001-09-28
HU226555B1 (en)	2009-03-30
NO20004788L (no)	2000-11-24
CZ20003525A3 (cs)	2001-04-11
EP1063995B1 (en)	2003-01-15
DE69904922D1 (de)	2003-02-20
ES2190205T3 (es)	2003-07-16
CZ296367B6 (cs)	2006-02-15

Legal Events

Date	Code	Title	Description
2014-12-04	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20140326

Publication	Publication Date	Title
US6512009B1 (en)	2003-01-28	Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US20010053777A1 (en)	2001-12-20	Drug treatment for restless leg syndrome
MXPA02011610A (es)	2003-05-14	Combinacion de sustancia activa que contiene un opioide que tiene una estructura tipo fentanilo y cetamina.
EA000976B1 (ru)	2000-08-28	Композиция для снятия боли и способ снятия боли
AU2025271432A1 (en)	2025-12-18	CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
KR20020081271A (ko)	2002-10-26	물질 남용의 치료 방법
CA2450787C (en)	2009-06-02	Active ingredient combination for pharmacological addictive substance or intoxicant therapy
AU2025279727A1 (en)	2026-01-15	Combinations of opioids and N-acylethanolamines
CZ20021116A3 (cs)	2003-05-14	Synergické kombinace antagonisty receptoru NK1 a strukturálního analogu GABA
US6026817A (en)	2000-02-22	Method of treating the syndrome of coronary heart disease risk factors in humans
CA2576385C (en)	2016-01-05	Novel formulation for l-tryptophane comprising carbidopa/benserazide
US20010034320A1 (en)	2001-10-25	NK1-receptor antagonists for treating restless legs syndrome
US20100203084A1 (en)	2010-08-12	Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
GB2163957A (en)	1986-03-12	Anti-asthma compositions containing ketotifen
MXPA02011611A (es)	2003-05-14	Combinacion de sustancia activa que contiene un compuesto con efecto opioide y por lo menos un compuesto adicional de formula i.
HK1032542B (en)	2003-07-25	Combination for the treatment of alcohol dependence containing an opioid antagonist and a nmda receptor complex modulator
RS20050738A (sr)	2008-04-04	Farmaceutska kombinacija za lečenje spastičnosti i/ili bola
MXPA00009257A (en)	2002-03-26	Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
KR20020063180A (ko)	2002-08-01	물질 탐닉 치료방법
WO2025198489A1 (ru)	2025-09-25	Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения
HK40014066A (en)	2020-08-14	Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions